PerkinElmer Highlights New Drug Discovery and Life Science Research Solutions at SBS 2011

At the Society for Biomolecular Sciences 2011 in Orlando, Florida, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment,will be showcasing several new drug discovery technologies and applications - including new products based on Alpha technology and a novel panel ofepigenetics-based detection reagents.

According to Martina Bielefeld-Sévigny, Ph.D., vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer, “PerkinElmer provides researchers in drug discovery and life sciences with the ability to approach targets from multiple perspectives; to locate, detect and quantifytheir targets of interest, to analyze and understand them in wider physiological contexts. Our ability to deliver reagents, instruments, knowledge and services, helps advance research and drug discovery with the translational data and analysis to help lead to breakthrough insights.”

PerkinElmer's SBS offerings will include the Company's expanded epigenetic detection reagents specifically validated for drug discovery and life sciences research for disease states including cancer, neurodegenerative and metabolic disorders, as well as applications for stem cells and immunology.Additionally, PerkinElmer will also feature the EnSpire®Multimode Plate Reader with new optical label-free detection, the first and only benchtop detection platform to combine Corning®Epic®label-free technology and traditional labeled assays to accurately identify and characterize potential new therapeutic targets.This combination of labeled and label-free detection technologies providesresearchers with a more complete and insightful view of their cellular and biochemical interactions.

PerkinElmer’s new technologies and assay expansions on display at SBS Booth 701 include:

• EnSpire Multimode Plate Reader with label-free technology
• Expanded target class coverage for Epigenetics, cellular kinases and protein-protein interactions
• Expansion of the AlphaLISA®research assaysto over 100 no-wash biomarker kits for a variety of therapeutic areas including neurodegeneration, cancer and virology
• Operetta® High Content Imaging System with new PhenoLOGIC™, machine-learning technology for intuitive cell classification
• PerkinElmer’s epigenetic and post-DNA translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).

Additional PerkinElmer products on display at SBS Booth 701 will include:

• FMT in vivo Imaging System
• Operetta®High Content Imaging System
• Columbus®Data Management Software
• Volocity®3D Imaging Software
• EnVision®Multilabel Plate Reader
• JANUS®Automated Workstation